Riboflavin Corneal Crosslinking for Brittle Cornea Syndrome and Ehlers-Danlos Syndrome Type VI
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Brittle Cornea Syndrome and Ehlers-Danlos Syndrome (EDS) type VI are rare collagen-connective
tissue disorders that predispose affected individuals to the development of perforated
corneas from the mildest of eye trauma or even spontaneously. Clinical studies evaluating
riboflavin-corneal crosslinking have found that it dramatically increases corneal rigidity.
Given the success and safety of riboflavin crosslinking, the investigators believe that it
can increase the corneal stability in patients affected these disseases, preventing
perforation. It is furthermore possible, that riboflavin crosslinking will allow corneal
transplants to successfully be performed on blind eyes that have already perforated and
opacified. The purpose of the study is to determine whether corneal crosslinking can be
safely performed on individuals with Brittle Cornea Syndrome or Ehlers-Danlos Syndrome type
VI.